Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

© 2015 John P. Bilezikian, Robert Marcus, and Michael A. Levine Published by Elsevier Inc. All rights reserved.. Primary hyperparathyroidism (PHPT) may occur as part of a complex syndrome or as an isolated (non-syndromic) disorder, and both of these forms can occur as hereditary (i.e., familial) or non-familial (i.e., sporadic) diseases. Syndromic forms of PHPT include multiple endocrine neoplasia (MEN) types 1 to 4 (MEN1 to MEN4), and the hyperparathyroidism-jaw tumor (HPT-JT) syndrome. MEN1 is caused by abnormalities of the MEN1 gene which encodes a tumor suppressor; MEN2 and MEN3 are due to mutations of the rearranged during transfection (. RET) proto-oncogene; MEN4 is due to mutations of a cyclin-dependent-kinase inhibitor (. CDNK1B); and HPT-JT is due to mutations of cell division cycle 73 (. CDC73) which encodes parafibromin. Non-syndromic PHPT, which may be familial and referred to as familial isolated hyperparathyroidism (FIHP), may also be due to mutations of the MEN1, CDC73, or calcium-sensing receptor (. CASR) genes. In addition, ≈10% of patients presenting below the age of 45 years with non-syndromic (sporadic) PHPT may have MEN1, CDC73, or CASR mutations, and overall more than 10% of patients with PHPT will have a mutation in one of 11 genes.

Original publication





Book title

The Parathyroids: Basic and Clinical Concepts: Third Edition

Publication Date



341 - 363